Pharmacovigilance in Clinical Trails
Abstract
Pharmacovigilance, the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug- related problems, is intrinsically linked to effective information management. The pivotal role of information in pharmacovigilance encompassing data collection, analysis, and dissemination for optimal patient safety. The foundation of pharmacovigilance lies in robust information system that facilitate the collection of adverse event reports from health-care professionals, Patients, and other stake holders’ Major purpose of pharmacovigilance is to gauge the benefit- risk profile of drug for better efficacy and safety to be used in patients. Pharmacovigilance plays a major role in rationale use of drug which provides the information about the adverse drug reactions which seen in patients. In terms of volume Indian Pharma industry is third largest in world and in terms of value id thirteen largest in world. India is also known as a hub for clinical research and drug development. A critical component throughout the drug development life- cycle is monitoring patient safety.
Keywords:
Pharmacovigilance, Clinical trials, Safety monitoring, stakeholders, Participant safety, Monitoring, reporting, Adverse events, Data integrity, Benefits and risksDOI
https://doi.org/10.70604/ijzels.v2i2.53References
1. Kanala K, Hwisa NT, Chandu BR, Assaleh FH, Mukkanti K, Katakam P, Challa BS. Simultaneous quantification of mesalamine and its metabolite N-acetyl mesalamine in human plasma by LC-MS/MS and its application to a bioequivalence study. British Journal of Pharmaceutical Research. 2014 Jul 1;4(13):1568.https://www.ijpsjournal.com
2. Härmark LV. Web-based intensive monitoring: a patient based pharmacovigilance tool.https://doi.org/10.36713/epra15259
3. Mastroianni PC, Varallo FB, Dagli-Hernandes C. Brazilian regulation in pharmacovigilance: a review. Pharm Regul Aff. 2016;5:164..: http://dx.doi.org/10.47583/ijpsrr.2021.v70i01.002
4. Silar S, Suryaprabha M, Chandu B, Nama S, Irfan P, Pathapati H, Pisipati SV. FEATAL ALCOHOL SYNDROME.
http://dx.doi.org/10.47583/ijpsrr.2021.v70i01.002
5. Singh BG, Baburao C, Pispati V, Pathipati H, Muthy N, Prassana SR, Rathode BG. Carbon nanotubes. A novel drug delivery system. International Journal of Research in Pharmacy and Chemistry. 2012;2(2):523-32.
https://link.springer.com/article/10.1007/s40264-018-0647-1,
6. Pisipati SV, Pathapati H, Bhukya G, Nuthakki S, Chandu B, Nama S, Adeps R. Lycopene: Redress for prostate cancer. Journal of basic and clinical pharmacy. 2012 May 15;3(2):261.
https://link.springer.com/article/10.2165/00002018-200427080-00008
7. Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the use of nonrandomized real‐world data analyses for regulatory decision making. Clinical Pharmacology & Therapeutics. 2019 Apr;105(4):867-77.
https://doi.org/10.1002/cpt.1351
8. Chisholm O, Sharry P, Phillips L. Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities. Frontiers in medicine. 2022 Jan 12;8:820335.
https://doi.org/10.1002/cpt.1351
9. Grady C. Payment of clinical research subjects. The Journal of clinical investigation. 2005 Jul 1;115(7):1681-7.
10. Archdeacon P, Grandinetti C, Vega JM, Balderson D, Kramer JM. Optimizing expedited safety reporting for drugs and biologics subject to an investigational new drug application. Therapeutic innovation & regulatory science. 2014 Mar;48(2):200-7.
https://doi.org/10.1177/2168479018768514
11. Textbooks P. Textbooks on pharmacovigilance may cover topics related to participant safety in clinical trials. Examples include “Pharmacovigilance: Principles and Database Systems” by Patrick Waller and “Pharmacovigilance: A Practical Approach” by Ronald D. Mann.
https://doi.org/10.1002/9780471462422.eoct064
12. Textbooks P. Textbooks on pharmacovigilance may cover topics related to participant safety in clinical trials. Examples include “Pharmacovigilance: Principles and Database Systems” by Patrick Waller and “Pharmacovigilance: A Practical Approach” by Ronald D. Mann.
https://doi.org/10.1002/9780471462422.eoct064
13. Dasari V, Awen BZ, Chandu BR, Khagga M. In-Vitro and In-Vivo Evaluation of Multi Unit Stavudine Gastroretentive Dosage Forms. Research Journal of Pharmaceutical Dosage Forms and Technology. 2010;2(5):344-53.
https://doi.org/10.1002/9780471462422.eoct064
14. Goldstein BA, Navar AM, Pencina MJ, Ioannidis JP. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. Journal of the American Medical Informatics Association: JAMIA. 2016 May 17;24(1):198..
Published
Abstract Display: 196
PDF Downloads: 177 How to Cite
Issue
Section

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/lapinjournals/domains/lapinjournals.com/public_html/plugins/generic/citations/CitationsPlugin.php on line 68
.